18Jul 2021
Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab

Integrated safety analysis of treatment‐emergent eczematous reactions in patients with moderate‐to‐severe psoriasis treated with ixekizumab, etanercept and ustekinumab

Eczema and eczematous reactions induced by interleukin (IL)‐17 inhibitors in patients with psoriasis are established adverse events (1), which may be reported as adverse events (AEs) in up to 12.1% patients on anti‐IL‐17 treatment in controlled clinical trials (2‐5). We performed an integrated safety analysis of 13 clinical studies to evaluate the frequency and management of the treatment‐emergent adverse events (TE‐AEs) of eczema and clinical variants in patients with moderate‐to‐severe psoriasis treated with ixekizumab (IXE),..

  • #dermatology

Like

Save

Share